Boston Partners Purchases New Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Boston Partners acquired a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 426,636 shares of the company’s stock, valued at approximately $15,778,000. Boston Partners owned 0.89% of Amphastar Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Intech Investment Management LLC increased its position in Amphastar Pharmaceuticals by 224.6% during the 4th quarter. Intech Investment Management LLC now owns 42,156 shares of the company’s stock worth $1,565,000 after purchasing an additional 29,167 shares in the last quarter. Wealthfront Advisers LLC bought a new stake in Amphastar Pharmaceuticals in the fourth quarter worth approximately $9,268,000. Tiemann Investment Advisors LLC bought a new stake in Amphastar Pharmaceuticals in the 4th quarter valued at about $258,000. Amundi lifted its holdings in shares of Amphastar Pharmaceuticals by 193.0% in the 4th quarter. Amundi now owns 19,583 shares of the company’s stock worth $717,000 after purchasing an additional 12,899 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 90.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,203 shares of the company’s stock valued at $156,000 after buying an additional 1,992 shares in the last quarter. 65.09% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Trading Up 0.2 %

AMPH opened at $27.91 on Friday. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of 9.30, a PEG ratio of 2.19 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a one year low of $25.89 and a one year high of $53.96. The business has a 50 day simple moving average of $32.07 and a two-hundred day simple moving average of $40.71. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now directly owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 27.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have commented on AMPH. Piper Sandler lowered shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $66.00 to $36.00 in a research note on Tuesday, February 4th. Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target on the stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.